NCT06633068 The Analgesic Efficacy of Perineural Nalbuphine as an Adjuvant to Bupivacaine in Ultrasound Guided Superficial Cervical Plexus Nerve Block for Thyroid Surgeries. A Double Blinded Randomized Controlled Trial.
| NCT ID | NCT06633068 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Cairo University |
| Condition | Intra and Postoperative Pain Management |
| Study Type | INTERVENTIONAL |
| Enrollment | 54 participants |
| Start Date | 2024-07-15 |
| Primary Completion | 2025-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 54 participants in total. It began in 2024-07-15 with a primary completion date of 2025-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aiming to evaluate the analgesic effect of adding nalbuphine as an adjuvant to bupivacaine in superficial cervical plexus block during thyroid surgeries regarding first rescue analgesia in the first twenty-four hours postoperative, VAS score after extubation and complications such as postoperative nausea, vomiting and respiratory depression.
Eligibility Criteria
Inclusion Criteria: * Patients aged between 18 to 60 years old of both sexes undergoing elective thyroid surgery. * ASA I and II. Exclusion Criteria: * Patient refusal. * Hypersensitivity or contraindication to nalbuphine or bupivacaine. * Pregnancy or lactating mothers. * Hepatic, cardiac or renal diseases. * Bleeding disorders. * Severe neurological or psychological disorders. * Goitres with retrosternal extension. * Any anatomical disruption in the neck (ex: metastatic lymph nodes).
Contact & Investigator
Marwa M Zayed, Assistant professor
STUDY DIRECTOR
Cairo University
Frequently Asked Questions
Who can join the NCT06633068 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Intra and Postoperative Pain Management. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06633068 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06633068 currently recruiting?
Yes, NCT06633068 is actively recruiting participants. Contact the research team at sarabadie1993@gmail.com for enrollment information.
Where is the NCT06633068 trial being conducted?
This trial is being conducted at Giza, Egypt.
Who is sponsoring the NCT06633068 clinical trial?
NCT06633068 is sponsored by Cairo University. The principal investigator is Marwa M Zayed, Assistant professor at Cairo University. The trial plans to enroll 54 participants.